Pentachloropseudilin

Research use only, not for human use.

Pentachloropseudilin (PClP) is a reversible variant 1 myosin inhibitor with antimicrobial activity that inhibits Myo1s and class 5 myosins.

Pentachloropseudilin (Antibiotic A 15104 Y; PClP) is a reversible and allosteric potent inhibitor of Myo1s (class 1 myosins) with IC50s range from 1 to 5 μM for mammalian class-1 myosins and greater than 90 μM for class-2 and class-5 myosins. Pentachloropseudilin is a potent inhibitor of transforming growth factor-β (TGF-β)-stimulated signaling, with an IC50 of 0.1 to 0.2 μM for TGF-β.

Pentachloropseudilin (PClP) inhibits TGF-β-stimulated Smad2/3 phosphorylation and plasminogen activator inhibitor-1 (PAI-1) promoter activation with an IC50 of 0.1 μM in target cells (A549, HepG2, and Mv1Lu cells).Pentachloropseudilin attenuates TGF-β-stimulated expression of vimentin, N-cadherin, and fibronectin and, thus, blocks TGF-β-induced epithelial to mesenchymal transition (EMT) in these cells.Pentachloropseudilin (0.05 to 1 μΜ; 0-6 hours) pretreatment inhibits TGF-β-mediated (50 or 100 pM) increases in p-Smad2/3 expression to 47% (Mv1Lu) and 79% (A549), respectively. Pentachloropseudilin (0.2 μM) suppresses TGF-β-stimulated cellular responses by attenuating cell-surface expression of the type II TGF-β receptor through accelerating caveolae-mediated internalization followed by primarily lysosome-dependent degradation of the receptor, as demonstrated by sucrose density gradient analysis and immune fluorescence staining.Pentachloropseudilin (200 μM; 24 hours) exhibits and altered cell viability in HUVECs.

——

——

Others

Other Targets

TGF-beta/Smad | Antibiotic | Myosin

——

——

69640-38-6

331.41

C10H4Cl5NO

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (301.74 mM; Ultrasonic )

Oc1c(Cl)cc(Cl)cc1-c1[nH]c(Cl)c(Cl)c1Cl

——

(-20℃)

With Ice Pack

≥ 2 years